- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02207101
Study to Assess the Effect of OXYJUN on Ejection Fraction and Markers of Cardiovascular Injury (Enduoxy)
The Effect of Investigational Product E-OJ-01 (OXYJUN) on Left Ventricular Ejection Fraction and Markers of Cardiovascular Injury.
Young athletes are usually regarded as a special subgroup of healthy individuals with a unique lifestyle who are apparently invulnerable and often capable of extraordinary physical achievement. Most athletic disciplines to some extent combine endurance and strength modes of physical conditioning. Acute responses to endurance exercise training include substantial increases in maximal oxygen uptake, cardiac output, stroke volume, and systolic blood pressure in-spite of this, high intensity chronic training such as marathons, very long distance bicycle racing etc., can lead to transient acute volume overload of the atria and right ventricle, with transient reductions in right ventricular ejection fraction and elevations of cardiac biomarkers. Although these biomarkers generally normalize back within seven to ten days, these transient changes may sooner or later mark the beginning of processes like patchy myocardial fibrosis finally leading to grave chronic heart diseases .
Inspite of the awareness regarding the cardio vascular risk in the athletes, there have been no new advancements in finding an alternate option which can protect the cardio vascular system in the athletes.
Hence in order to address the need of the hour and also to avoid the cardio vascular risk in athletes along with improvising the endurance capacity, Enovate Biolife is in the process of development of an innovative product "E-OJ-01".
E-OJ-01 is expected to have beneficial effects on the cardio vascular system of the athletes by enhancing ejection fraction which in turn improves cardiac output. This finally is hypothysed to increase the maximal oxygen uptake capacity in athletes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400053
- Suburban Diagnostics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male athletes aged 18 - 40 years having endurance exercise not less than 3-4 hrs. / week since at least last 12 weeks.
- Subject with left ventricular ejection fraction not less than 55% and not more than 70%.
- Subjects having body fat less than 16% as determined by skin fold assessment.
- Subject is willing to refrain from vigorous physical activity 12 hrs prior to clinic visit.
- Subject is a non-alcoholic/ non-smoker.
- Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
Exclusion Criteria:
- Left Ventricular Ejection fraction less than 55 per cent by echocardiogram.
- Subjects suffering from anemia as defined by Hb levels ≤ 10 g/ dl.
- Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥ 100 mm Hg) as defined by the average blood pressure measured at screening.
- History of coronary artery disease, myocardial infarction, hypertension or diabetes mellitus.
- History of cardiomyopathy, congenital heart defect, open heart surgery, or ongoing arrhythmia.
- Subjects having laboratory finding beyond specified normal limits at screening and in the opinion of the investigator possess significant threat for the study subject.
- Subject has a history or presence of clinically important renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorders that, in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the subject at undue risk.
- Use of any sleep aid medication within four days prior to each test day.
- Use of any psychotropic medication within four weeks of screening and throughout the study.
- Subject has a history, in the judgment of the Investigator, of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
- Use of antibiotics or signs of active systemic infection. Treatment visits will be rescheduled to allow the subject to wash off of the antibiotic for at least five days prior to any test visit. Use of any other dietary supplements or herbal products.
- Recent history of (within 12 months of screening visit 1) or strong potential for alcohol or substance abuse.
- Subject has a known allergy or sensitivity to herbal product(s).
- Subject has had exposure to any non-registered drug product within 30 days prior to the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: E-OJ-01 (OXYJUN)
E-OJ-01 (OXYJUN).
Dose: 01 capsule to be taken orally daily after lunch.
|
|
Placebo Comparator: Placebo
Matching placebo capsules [for E-OJ-01 (OXYJUN)] composed of microcrystalline cellulose.
Dose: 01 capsule to be taken orally daily after lunch.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Left Ventricular Ejection Fraction
Time Frame: Day 0, Day 28 and Day 56
|
Day 0, Day 28 and Day 56
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Serum Troponin-T
Time Frame: Day 0 and Day 56
|
Day 0 and Day 56
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ravi Chavan, MD
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- EB/141005/OXY-2/CE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Function in Young Athletes
-
Istituto per la Ricerca e l'Innovazione BiomedicaCompleted
-
Universitaire Ziekenhuizen KU LeuvenJessa Hospital; Algemeen Ziekenhuis Maria MiddelaresCompletedAdolescent | Biomarker | Exercise Induced Bronchoconstriction | Young AthletesBelgium
-
PepsiCo Global R&DCompletedFluid Intake in Athletes | Sweating Rate in Athletes | Sweat Chloride Concentration in AthletesUnited States
-
University of ArizonaUniversity of North Texas Health Science CenterRecruitingEffectiveness of BIM in Reducing Disordered Eating Among Student Athletes | Effectiveness of BIM in Reducing Body Image Concerns Among Student Athletes | Effectiveness of BIM Improving Psychological Well-Being Among Student AthletesUnited States
-
University of Alabama, TuscaloosaEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingSecond Language Acquisition in Healthy Young AdultsUnited States
-
National Taiwan University HospitalUnknownVital Pulp Therapy in Young Permanent ToothTaiwan
-
Swansea UniversityBeneo GmbHNot yet recruitingA Randomised Counter-balanced Intervention Study in Endurance Athletes
-
Swiss Federal Institute of TechnologyCompletedEffects of Exergaming on Cognitive Functions in Young AthletenSwitzerland
-
Assiut UniversityCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States